Suscribirse

Correlation between Serum Caffeine Levels and Changes in Cytokine Profile in a Cohort of Preterm Infants - 02/08/11

Doi : 10.1016/j.jpeds.2010.06.051 
Raul Chavez Valdez, MD a, b, Rajni Ahlawat, MD a, Marsha Wills-Karp, PhD c, Amy Nathan, MD c, Tarrah Ezell d, Estelle B. Gauda, MD a
a Department of Pediatrics, Division of Neonatology, Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD 
b Department of Pediatrics, Division of Neonatology, Texas Tech University – Health Sciences Center, Odessa, TX 
c Division of Immunology, Children's Hospital of Cincinnati, University of Cincinnati College of Medicine, Cincinnati, OH 
d Department of Biology, Morgan State University, Baltimore, MD 

Abstract

Objective

To determine changes in cytokine levels associated with caffeine treatment in a cohort of preterm infants.

Study design

For this observational prospective study, we collected clinical data from 26 preterm infants (≤30 weeks gestational age). In addition to caffeine levels, cytokine profiles in peripheral blood (PB) and tracheal aspirates (TA) were determined with enzyme-linked immunosorbent assay at birth, before and after (at 24 hours and 1 week) initiation of caffeine. Non-parametric statistics were applied.

Results

Included infants were 26.9 ± 1.7 weeks gestational age and weighed 985 ± 202 g. At birth, all cytokine concentrations were significantly greater in TA than PB. Serum caffeine levels were 11.1 μg/mL (interquartile range, 1.85) at approximately 24 hours post-load and 16.4 (8.7) μg/mL at 1 week on treatment. At approximately 24 hours post-load, interleukin (IL)-10 levels decreased by 47.5% (P = .01) in PB and 38.5% (P = .03) in TA, whereas other cytokine levels remained unchanged. At 1 week, caffeine levels were correlated (U-shaped) with changes in proinflammatory tumor necrosis factor-⍺ (R2 = 0.65; P = .0008), interleukin (IL)-1β (R2 = 0.73; P = .0007), and IL-6 (R2 = 0.59; P = .003), whereas inversely correlated (linear) with the anti-inflammatory IL-10 (R2 = 0.64; P = .0008). Altogether, caffeine, at serum levels ≥20 μg/mL, was associated with a proinflammatory profile after 1 week of treatment.

Conclusions

Caffeine treatment for apnea of prematurity correlates with changes in cytokine profile. Caffeine levels ≥20 μg/mL are associated with a proinflammatory profile in our cohort of preterm infants.

El texto completo de este artículo está disponible en PDF.

Mots-clés : AR, BPD, BUN, cAMP, CBC, ETT, GA, GM-CSF, IL, INF, IQR, LLD, MV, PB, SNAP, TA, TNF


Esquema


 Supported by grants from Johns Hopkins University School of Medicine General Clinical Research Center (M01-RR00052), the National Center for Research Resources (NCRR)/The National Institutes of Health (NIH) (HL-072748 to E.B.G), Johns Hopkins University Institutional Research Grant, and the Thomas Wilson Sanitarium for Children of Baltimore City. The authors declare no conflicts of interest.


© 2011  Mosby, Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 158 - N° 1

P. 57 - janvier 2011 Regresar al número
Artículo precedente Artículo precedente
  • Development of Preschool and Academic Skills in Children Born Very Preterm
  • Cornelieke Sandrine Hanan Aarnoudse-Moens, Jaap Oosterlaan, Hugo Joseph Duivenvoorden, Johannes Bernard van Goudoever, Nynke Weisglas-Kuperus
| Artículo siguiente Artículo siguiente
  • Aerobic Fitness and Physical Activity Levels of Children Born Prematurely following Randomization to Postnatal Dexamethasone
  • Patricia A. Nixon, Lisa K. Washburn, Lanay M. Mudd, Heather H. Webb, T. Michael O'Shea

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.